For sponsors developing non-GLP-1 peptide programmes in oncology, rare disease, or other therapeutic areas, the competition for the same SPPS reactor capacity, the same HPLC purification infrastructure, and the same analytical characterisation capability has materially lengthened lead times and elevated costs
Although generic versions will be available soon in most countries, such as China, India, and Canada, generics wont likely be available in the US until the early 2030s
We will support you in all aspects of PEGylation from the laboratory R&D level to the scale-up level.) Polymer-Based Sustained-Release Formulations : Developing sustained-release formulations to extend the drug's release time in the body
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist a medication that mimics the action of GLP-1, a naturally occurring hormone produced in the gut in response to eating